BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35789054)

  • 1. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective.
    Lücking U
    Chemistry; 2022 Oct; 28(56):e202201993. PubMed ID: 35789054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfoximines: a neglected opportunity in medicinal chemistry.
    Lücking U
    Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
    Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
    Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
    Mäder P; Kattner L
    J Med Chem; 2020 Dec; 63(23):14243-14275. PubMed ID: 32870008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
    Tomaselli D; Mautone N; Mai A; Rotili D
    Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery.
    Frings M; Bolm C; Blum A; Gnamm C
    Eur J Med Chem; 2017 Jan; 126():225-245. PubMed ID: 27821325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Transformations of NH-Sulfoximines.
    Andresini M; Tota A; Degennaro L; Bull JA; Luisi R
    Chemistry; 2021 Dec; 27(69):17293-17321. PubMed ID: 34519376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets.
    Poso A
    J Med Chem; 2021 Aug; 64(15):10680-10681. PubMed ID: 34296872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 17
    Ciulli A; O'Connor S; Chung CW; Hartung IV; Testa A; Daniels DL; Heitman LH
    ChemMedChem; 2023 Oct; 18(20):e202300464. PubMed ID: 37817354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent fragment approaches targeting non-cysteine residues.
    Csorba N; Ábrányi-Balogh P; Keserű GM
    Trends Pharmacol Sci; 2023 Nov; 44(11):802-816. PubMed ID: 37770315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.
    Boulard E; Zibulski V; Oertel L; Lienau P; Schäfer M; Ganzer U; Lücking U
    Chemistry; 2020 Apr; 26(19):4378-4388. PubMed ID: 31961028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
    Hillebrand L; Liang XJ; Serafim RAM; Gehringer M
    J Med Chem; 2024 May; 67(10):7668-7758. PubMed ID: 38711345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation development of antibody-drug conjugates.
    Galush WJ; Wakankar AA
    Methods Mol Biol; 2013; 1045():217-33. PubMed ID: 23913150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.
    Ma Y; Frutos-Beltrán E; Kang D; Pannecouque C; De Clercq E; Menéndez-Arias L; Liu X; Zhan P
    Chem Soc Rev; 2021 Apr; 50(7):4514-4540. PubMed ID: 33595031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.